These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24200269)

  • 1. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
    Ramachandran G; Bhavani PK; Hemanth Kumar AK; Srinivasan R; Raja K; Sudha V; Venkatesh S; Chandrasekaran C; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1564-8. PubMed ID: 24200269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
    Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.
    Jenks JD; Kumarasamy N; Ezhilarasi C; Poongulali S; Ambrose P; Yepthomi T; Devaraj C; Benson CA
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1181-4. PubMed ID: 27510243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
    Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
    Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
    Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
    BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
    Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
    Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
    Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
    Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
    PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.